The instant disclosure relates to methods for preventing, controlling and/or inhibiting the rare events of adventitious viral infection or viral replication/amplification after reactivation of latent viral infection during cell culture in the manufacturing process of cell-based drug products, including CAR T cell drug products. Also provided are in vitro cell culture models for HHV-6 latent infection and methods of making the same.